Clinical Trial Search

Primary: Number of Participants Achieving an Assessment of Spondyloarthritis International Society (ASAS) 40 Response — 14; 33 participants — p=<0.001

Primary: Change From Baseline in Neuropsychiatric Inventory (NPI) Psychosis Subscale Score at Week 10 in Acute Phase — 12.12; 12.29; -5.52; -6.55 Units on a scale — p=0.802

Primary: Time to Recurrence of Any Mood Symptoms (Manic or Depressive) Associated With Bipolar I Disorder — 85.0; 140.0; 541; 283.0 Days — p=0.017

Primary: To Assess if Probiotic Prophylaxis (BIO-K+CL1285®) is Effective for the Prevention of AAD in Hospitalized Patients. — 84; 85; 86 participants — p==0.02

Primary: Centrally Confirmed Symptomatic Recurrent Venous Thrombotic Events (VTE) Including Unexplained Death During the Intended Treatment Period — 3; 37 Participants — p=<0.0001

Primary: Summary of Treatment Emergent Adverse Events (TEAE). — 176; 65; 102; 34 participants

Primary: Sum of Pain Intensity Difference (SPID) for Low Back Pain - Summary Statistics at 120 Hours (With Imputation) — 264.6; 264.0 Units on a scale — p=0.9703

Primary: Change in Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Level From Baseline to Week 12. — -3.852; -4.175; -4.374 log10 copies/mL

Primary: Change Between Baseline Evaluation Period and Treatment Evaluation Period in the Number of Days With Dysmenorrheic Pain — -4.6; -4.2 Days

Primary: Summary of Treatment Emergent Adverse Events (TEAE). — 205; 39; 46; 7 participants

Primary: Change in Western Ontario and McMaster Universities (WOMAC) Pain Questionnaire Subscore From Baseline — -43.4; -41.1; -34.0 mm

Primary: Summary of Change From Day 3 to Day 1 in Maximum Anti-Factor Xa (aFXa) — 1.66; 1.83 IU/ml — p=.008

Primary: Urinary Free Cortisol (UFC) — 0.86; 1.03 Ratio

Primary: Summary of Treatment Emergent Adverse Events (TEAE). — 264; 94; 77; 37 Participants

Primary: Safety Assessment in Terms of Adverse Events (Treatment-emergent [TEAEs] and Serious [SAEs]) — 301; 246; 178; 2 Participants